Fosravuconazole - Seren Pharmaceuticals

Drug Profile

Fosravuconazole - Seren Pharmaceuticals

Alternative Names: BFE-1224; BMS-379224; E-1224; Fosravuconazole L-lysine ethanolate; NAILIN; Ravuconazole prodrug - Eisai

Latest Information Update: 19 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Drugs for Neglected Diseases Initiative Foundation; Eisai Co Ltd; Seren Pharmaceuticals
  • Class Antifungals; Antiprotozoals; Fluorobenzenes; Small molecules; Thiazoles; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Onychomycosis
  • Phase II Chagas disease; Dermatomycoses
  • Discontinued Mycoses

Most Recent Events

  • 11 Jul 2018 Sato Pharmaceutical and Eisai Co Ltd will launch fosravuconazole (NAILIN®) 100mg capsules for Onychomycosis in Japan on July 27, 2018
  • 19 Jan 2018 Registered for Onychomycosis in Japan - First global approval (PO)
  • 31 Jan 2017 Preregistration for Onychomycosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top